Free reads
5 reportsOpen to everyone, in full — the same as members get them.
Business update01 Oct12 min read
Sai Life Sciences: Building the Next Leg of Growth
FY26 showed what Sai Life Sciences looks like when revenue scales: 29% sales growth, EBITDA up 56% and margins from 25% to 30%. Now it is committing the largest capex programme in its history. This note is open to everyone, free to read in full.
Business update17 Sept4 min read
What you get as an F2F member
F2F (Forest to Flower) is my research membership on Indian markets: company deep dives, results analysis, sector and macro reads, audio notes, and answers to your own questions. Here is exactly what is inside, what it costs, and how to join.
Business update04 Sept13 min read
Indo-MIM: strong numbers, but FY26 raises important questions
A newly listed company where the core is now the thing to track. Revenue grew 26%, but more than half the increment came from a loosely defined segment nobody has broken out.
Business update04 Sept12 min read
Electronics Mart India: strong Q1, but the real story starts now
The stock jumped after a blockbuster quarter. The bigger question is how to track this going forward — starting with the base it was measured against.
Business update17 Aug10 min read
Lenskart is screaming growth and we must not miss it
Lenskart is a growth story that if executed well, can create the next multibagger — but execution is the key.